2019年人类免疫缺陷病毒1型耐药性突变的更新情况。
2019 update of the drug resistance mutations in HIV-1.
作者信息
Wensing Annemarie M, Calvez Vincent, Ceccherini-Silberstein Francesca, Charpentier Charlotte, Günthard Huldrych F, Paredes Roger, Shafer Robert W, Richman Douglas D
机构信息
University Medical Center Utrecht, The Netherlands and University of the Witwatersrand, Johannesburg, South Africa.
Pierre et Marie Curie University and Pitié-Salpêtrière Hospital, Paris, France.
出版信息
Top Antivir Med. 2019 Sep;27(3):111-121.
Abstract
The 2019 edition of the IAS-USA drug resistance mutations list updates the Figure last published in January 2017. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The Figure is designed to assist practitioners in identifying key mutations associated with resistance to antiretroviral drugs, and therefore, in making clinical decisions regarding antiretroviral therapy.
摘要
美国抗逆转录病毒学会（IAS-USA）2019年版耐药性突变列表更新了上一次于2017年1月发布的图表。列出的突变是根据针对所述证据和药物的特定标准确定的。该图表旨在帮助从业者识别与抗逆转录病毒药物耐药性相关的关键突变，从而在抗逆转录病毒治疗方面做出临床决策。
相似文献
1
2019 update of the drug resistance mutations in HIV-1.
Top Antivir Med. 2019 Sep;27(3):111-121.
2
Update of the drug resistance mutations in HIV-1: Fall 2006.
Top HIV Med. 2006 Aug-Sep;14(3):125-30.
3
2022 update of the drug resistance mutations in HIV-1.
Top Antivir Med. 2022 Oct;30(4):559-574.
4
Update of the drug resistance mutations in HIV-1: Fall 2005.
Top HIV Med. 2005 Oct-Nov;13(4):125-31.
5
2015 Update of the Drug Resistance Mutations in HIV-1.
Top Antivir Med. 2015 Oct-Nov;23(4):132-41.
6
[Evolution of HIV resistance mutations in the Valme referral center].
Enferm Infecc Microbiol Clin. 2007 Feb;25(2):159. doi: 10.1016/s0213-005x(07)74247-7.
7
Changes in the rate of genotypic resistance to antiretroviral drugs in Spain.
AIDS. 2001 Sep 28;15(14):1894-6. doi: 10.1097/00002030-200109280-00025.
8
Antiretroviral Resistance Mutations (revised April 2001).
HIV Clin Trials. 2001 Jul-Aug;2(4):346-55. doi: 10.1310/8FXB-B0EK-D525-BVU3.
9
Update of the Drug Resistance Mutations in HIV-1.
Top HIV Med. 2008 Dec;16(5):138-45.
10
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
Antimicrob Agents Chemother. 2004 Feb;48(2):644-7. doi: 10.1128/AAC.48.2.644-647.2004.
引用本文的文献
1
In Silico identification and modelling of FDA-approved drugs targeting T-type calcium channels.
PLoS One. 2025 Aug 8;20(8):e0327386. doi: 10.1371/journal.pone.0327386. eCollection 2025.
2
Consensus Sequences for and Introduced into HIV-1 Clade B Laboratory Strains Differentially Influence the Impact of Point Mutations Associated with Immune Escape and with Drug Resistance on Viral Replicative Capacity.
Viruses. 2025 Jun 12;17(6):842. doi: 10.3390/v17060842.
3
Imiquimod, a Promising Broad-Spectrum Antiviral, Prevents SARS-CoV-2 and Canine Coronavirus Multiplication Through the MAPK/ERK Signaling Pathway.
Viruses. 2025 May 31;17(6):801. doi: 10.3390/v17060801.
4
Evolutionary Sequence and Structural Basis for the Epistatic Origins of Drug Resistance in HIV.
bioRxiv. 2025 May 2:2025.04.30.651576. doi: 10.1101/2025.04.30.651576.
5
Liquid Chromatography-Mass Spectrometry Metabolomic Analysis of Exell. Fruit Extracts That Inhibit HIV-1 Cell Infection, HIV-1 Reverse Transcriptase and HIV-1 Protease.
Molecules. 2025 Apr 10;30(8):1701. doi: 10.3390/molecules30081701.
6
Critical Care Pharmacology of Antiretroviral Therapy in Adults.
Eur J Drug Metab Pharmacokinet. 2025 Mar;50(2):105-118. doi: 10.1007/s13318-025-00934-7. Epub 2025 Feb 12.
7
Cyclophilin A Regulates Tripartite Motif 5 Alpha Restriction of HIV-1.
Int J Mol Sci. 2025 Jan 9;26(2):495. doi: 10.3390/ijms26020495.
8
Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir.
Viruses. 2024 Dec 6;16(12):1888. doi: 10.3390/v16121888.
9
Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV.
PLoS One. 2024 Nov 20;19(11):e0314003. doi: 10.1371/journal.pone.0314003. eCollection 2024.
10
Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study.
J Int Assoc Provid AIDS Care. 2024 Jan-Dec;23:23259582241269837. doi: 10.1177/23259582241269837.
本文引用的文献
1
Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection.
Nat Commun. 2019 May 1;10(1):2005. doi: 10.1038/s41467-019-10047-w.
2
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
Clin Infect Dis. 2019 Feb 1;68(4):535-544. doi: 10.1093/cid/ciy540.
3
Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Retrovirology. 2018 Aug 17;15(1):56. doi: 10.1186/s12977-018-0440-3.
4
Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel.
Clin Infect Dis. 2019 Jan 7;68(2):177-187. doi: 10.1093/cid/ciy463.
5
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.
JAMA. 2018 Jul 24;320(4):379-396. doi: 10.1001/jama.2018.8431.
6
Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.
Retrovirology. 2018 May 16;15(1):37. doi: 10.1186/s12977-018-0420-7.
7
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Lancet HIV. 2018 May;5(5):e211-e220. doi: 10.1016/S2352-3018(18)30021-3. Epub 2018 Mar 25.
8
Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01695-17. Print 2017 Dec.
9
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Lancet. 2017 Nov 4;390(10107):2073-2082. doi: 10.1016/S0140-6736(17)32340-1. Epub 2017 Aug 31.
10
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31.
Zotero 插件